A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
Key facts
- Who runs it
- Regeneron Pharmaceuticals
- Where
- Belgium, Bulgaria, Canada, Hungary, Latvia, Lithuania, and Poland16 sites in 7 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 373 people enrolled
- Started
- 24 May 2023
- Ended
- 27 May 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- REGN9933
- Enoxaparin
- Apixiban
- Record updated
- 29 August 2025
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Undergoing elective unilateral TKA
- Has a body weight ≤130 kg at screening visit
- Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and Electrocardiograms (ECG) performed at screening and/or prior to administration of initial dose of study drug
- Is in good health based on laboratory safety testing obtained during the screening period as described in the protocol
Who cannot take part
- History of bleeding in the past 6 months requiring hospitalization or transfusion; history of intracranial or intraocular bleeding, excessive operative or post-operative bleeding, and traumatic spinal or epidural anesthesia; history of bleeding diathesis
- History of thromboembolic disease or thrombophilia
- History of major surgery, including brain, spinal, or ocular, within approximately the past 6 months
- History of major trauma within approximately the past 6 months
- Using the Modification of Diet in Renal Disease equation, has an estimated glomerular filtration rate as described in the protocol; Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
- Hospitalized (>24 hours) for any reason within 30 days of the screening visit
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of the study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (VTE) after unilateral total knee arthroplasty (TKA), compared to enoxaparin
Read full original descriptionShow less
The secondary objectives of the study are:
* To evaluate the bleeding risk (ie, major and clinically relevant non-major [CRNM] bleeding) of REGN9933 after unilateral TKA through time of venography, compared to enoxaparin * To assess overall safety and tolerability of REGN9933 in participants undergoing TKA * To evaluate the efficacy of REGN9933 in prevention of clinically relevant VTE, compared to enoxaparin * To evaluate the efficacy of REGN9933 in prevention of deep venous thrombosis (DVT) detected by venography, compared to enoxaparin * To evaluate the pharmacokinetics (PK) of REGN9933 after single intravenous (IV) administration * To assess pharmacodynamic (PD) effects of REGN9933 on intrinsic and extrinsic coagulation pathways * To assess immunogenicity following a single dose of REGN9933 over time * To compare the efficacy of enoxaparin and apixaban in prevention of VTE after unilateral TKA
The 3 groups in the trial
- REGN9933Treatment being tested
REGN9933 will be administered by intravenous (IV) infusion
- EnoxaparinExisting treatment, for comparison
Enoxaparin will be administered by subcutaneous (SC) administration
- ApixabanExisting treatment, for comparison
Apixaban will be administered orally twice a day
Treatment: Apixiban
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty
- Publications
- Record updated
- 29 August 2025